Outcome of patients with nasal natural killer (NK)/T-cell lymphoma treated with radiotherapy, with or without chemotherapy

Background. This study reviews the outcome of patients with nasal natural killer (NK)/T‐cell lymphoma treated at the Therapeutic Radiology Department, National Cancer Centre, Singapore, from 1997 to 2003. Methods. Twenty‐one consecutive patients treated with radiotherapy, with or without chemotherap...

Full description

Saved in:
Bibliographic Details
Published in:Head & neck 2006-02, Vol.28 (2), p.126-134
Main Authors: Tham, Ivan Weng Keong, Lee, Khai Mun, Peng Yap, Swee, Loong, Susan Li-Er
Format: Article
Language:English
Subjects:
Adult
Age
Aged
Aged, 80 and over
Biological and medical sciences
Chemotherapy
Combined Modality Therapy
Female
Follow-Up Studies
Head
Hematologic and hematopoietic diseases
Humans
Killer Cells, Natural
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
lymphoma
Lymphoma, T-Cell - drug therapy
Lymphoma, T-Cell - mortality
Lymphoma, T-Cell - radiotherapy
Male
Medical sciences
Middle Aged
nasal
natural-killer
Neck
Nose Neoplasms - drug therapy
Nose Neoplasms - mortality
Nose Neoplasms - radiotherapy
Otorhinolaryngology. Stomatology
Prognosis
Radiology
Radiotherapy
Radiotherapy Dosage
Remission
Reviews
Survival
Survival Rate
T-cell lymphoma
Treatment Failure
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background. This study reviews the outcome of patients with nasal natural killer (NK)/T‐cell lymphoma treated at the Therapeutic Radiology Department, National Cancer Centre, Singapore, from 1997 to 2003. Methods. Twenty‐one consecutive patients treated with radiotherapy, with or without chemotherapy, were retrospectively reviewed. Results. The median age was 44 years (range, 27–86 years). Thirteen patients had stage I disease, five had stage II disease, and three had stage IV disease. Immunophenotyping was CD 56+ in 18 patients. Median follow‐up for patients still alive was 23.4 months (range, 8.9–78.5 months). A median dose of 50 Gy (range, 35–56 Gy) was delivered. Sixteen patients also received chemotherapy. Two‐year overall survival was 52.8%. Five patients had rapidly progressive disease, with a median survival of 89 days from diagnosis. The other 16 patients had complete remission, after which four relapsed. There were two local relapses. Conclusions. This disease often carries a poor prognosis, despite multimodality treatment. Radiotherapy may contribute to local control in some patients. © 2005 Wiley Periodicals, Inc. Head Neck 27: XXX–XXX, 2005
ISSN:1043-3074
1097-0347
DOI:10.1002/hed.20314